These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36547186)

  • 1. Survey of Anaphylaxis during Rasburicase Re-Administration in Patients with Hematological Malignancies Using a Japanese Claims Database.
    Kobayashi S; Yasu T; Akazawa M
    Curr Oncol; 2022 Dec; 29(12):9826-9832. PubMed ID: 36547186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose rasburicase in hematologic malignancies.
    Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
    Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
    Goldman SC
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):429-33. PubMed ID: 12934655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
    Kobayashi S; Yasu T; Sato K; Ohno N; Kuroda S
    Gan To Kagaku Ryoho; 2018 May; 45(5):879-881. PubMed ID: 30026457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
    Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis and protocolization of rasburicase use in patients with hematologic neoplasms].
    Llinares F; Burgos A; Fernández P; Villarrubia B; Ferrandis P; Ordovás JP
    Farm Hosp; 2006; 30(2):92-8. PubMed ID: 16796422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
    Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
    Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
    Shin HY; Kang HJ; Park ES; Choi HS; Ahn HS; Kim SY; Chung NG; Kim HK; Kim SY; Kook H; Hwang TJ; Lee KC; Lee SM; Lee KS; Yoo KH; Koo HH; Lee MJ; Seo JJ; Moon HN; Ghim T; Lyu CJ; Lee WS; Choi YM
    Pediatr Blood Cancer; 2006 Apr; 46(4):439-45. PubMed ID: 16123985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
    Brant JM
    Clin J Oncol Nurs; 2002; 6(1):12-6. PubMed ID: 11842483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.